{"title":"Ginsenoside Re increases human coronary artery endothelial SK<sub>Ca</sub> current and nitric oxide release via glucocorticoid receptor-PI3K-Akt/PKB pathway.","authors":"Kitinat Rodthongdee, Wattana B Watanapa, Katesirin Ruamyod, Namoiy Semprasert, Pimchanok Nambundit, Suwattanee Kooptiwut, Luecha Boontaveekul","doi":"10.1016/j.jgr.2025.04.008","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ginsenoside Re (Re) has been shown to activate small-conductance calcium-activated potassium (SK<sub>Ca</sub>) current in human coronary artery endothelial cells (HCAECs). We aimed to investigate whether Re increased SK<sub>Ca</sub> current via glucocorticoid receptor (GR), its non-genomic pathway phosphoinositide 3-kinase-protein kinase B (PI3K-Akt/PKB), and endothelial nitric oxide synthase (eNOS), and whether SK<sub>Ca</sub> mediated Re-induced increase in nitric oxide (NO), prostacyclin (PGI<sub>2</sub>), epoxyeicosatrienoic acid (EET), and/or hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>).</p><p><strong>Methods: </strong>Whole-cell patch clamp technique was employed to study Re-activated HCAEC currents, using specific inhibitors of the proposed mediating pathway. NO and H<sub>2</sub>O<sub>2</sub> were assayed with colorimetric methods; PGI<sub>2</sub> and EET were investigated using ELISA. eNOS phosphorylation was assessed using Western blot analysis.</p><p><strong>Results: </strong>Re (1 μM) significantly increased HCAEC whole-cell current at +80 mV to 173.73 ± 43.90 % (mean ± SD). Apamin (SK<sub>Ca</sub> blocker) could virtually eliminate Re-induced current and apamin-insensitive current could not be increased by Re, while blockers of other endothelial potassium channels did not produce the same effects. Moreover, antagonists of GR, PI3K, Akt/PKB, and eNOS effectively prevented Re's action. Re-induced eNOS phosphorylation and NO production could be prevented by blockers of SK<sub>Ca</sub>, GR, or Akt/PKB, but Re-induced PGI<sub>2</sub> production could not be prevented by apamin, while EET and H<sub>2</sub>O<sub>2</sub> were not increased by Re.</p><p><strong>Conclusion: </strong>Re enhances SK<sub>Ca</sub> current and NO production via GR-PI3K-Akt/PKB and eNOS activation; in turn, SK<sub>Ca</sub> current is essential for Re-increased NO. However, Re-induced PGI<sub>2</sub> release is independent of SK<sub>Ca</sub> current. These findings could facilitate further research about ginseng effects on coronary artery and possible use in cardiovascular diseases.</p>","PeriodicalId":16035,"journal":{"name":"Journal of Ginseng Research","volume":"49 5","pages":"523-531"},"PeriodicalIF":5.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12365508/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ginseng Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jgr.2025.04.008","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Ginsenoside Re (Re) has been shown to activate small-conductance calcium-activated potassium (SKCa) current in human coronary artery endothelial cells (HCAECs). We aimed to investigate whether Re increased SKCa current via glucocorticoid receptor (GR), its non-genomic pathway phosphoinositide 3-kinase-protein kinase B (PI3K-Akt/PKB), and endothelial nitric oxide synthase (eNOS), and whether SKCa mediated Re-induced increase in nitric oxide (NO), prostacyclin (PGI2), epoxyeicosatrienoic acid (EET), and/or hydrogen peroxide (H2O2).
Methods: Whole-cell patch clamp technique was employed to study Re-activated HCAEC currents, using specific inhibitors of the proposed mediating pathway. NO and H2O2 were assayed with colorimetric methods; PGI2 and EET were investigated using ELISA. eNOS phosphorylation was assessed using Western blot analysis.
Results: Re (1 μM) significantly increased HCAEC whole-cell current at +80 mV to 173.73 ± 43.90 % (mean ± SD). Apamin (SKCa blocker) could virtually eliminate Re-induced current and apamin-insensitive current could not be increased by Re, while blockers of other endothelial potassium channels did not produce the same effects. Moreover, antagonists of GR, PI3K, Akt/PKB, and eNOS effectively prevented Re's action. Re-induced eNOS phosphorylation and NO production could be prevented by blockers of SKCa, GR, or Akt/PKB, but Re-induced PGI2 production could not be prevented by apamin, while EET and H2O2 were not increased by Re.
Conclusion: Re enhances SKCa current and NO production via GR-PI3K-Akt/PKB and eNOS activation; in turn, SKCa current is essential for Re-increased NO. However, Re-induced PGI2 release is independent of SKCa current. These findings could facilitate further research about ginseng effects on coronary artery and possible use in cardiovascular diseases.
期刊介绍:
Journal of Ginseng Research (JGR) is an official, open access journal of the Korean Society of Ginseng and is the only international journal publishing scholarly reports on ginseng research in the world. The journal is a bimonthly peer-reviewed publication featuring high-quality studies related to basic, pre-clinical, and clinical researches on ginseng to reflect recent progresses in ginseng research.
JGR publishes papers, either experimental or theoretical, that advance our understanding of ginseng science, including plant sciences, biology, chemistry, pharmacology, toxicology, pharmacokinetics, veterinary medicine, biochemistry, manufacture, and clinical study of ginseng since 1976. It also includes the new paradigm of integrative research, covering alternative medicinal approaches. Article types considered for publication include review articles, original research articles, and brief reports.
JGR helps researchers to understand mechanisms for traditional efficacy of ginseng and to put their clinical evidence together. It provides balanced information on basic science and clinical applications to researchers, manufacturers, practitioners, teachers, scholars, and medical doctors.